Isomorphic Labs, the AI drug design company founded by Google DeepMind’s Demis Hassabis, has raised $5 billion in a Series C round. Announced in London on 17 November 2026, the round was co-led by Greenoaks and Sequoia Capital and includes continued investment from Alphabet. It comes about six months after the company’s previous $2.1 billion round, according to Tech.eu.
Quick Take
- Amount: $5 billion Series C, described as oversubscribed. The company did not disclose a valuation.
- Lead investors: Greenoaks and Sequoia Capital, alongside Andreessen Horowitz and several new investors, with continued significant investment from Alphabet.
- Existing investors: Thrive Capital, MGX, GV, CapitalG, Temasek and the UK Sovereign AI Fund all took part.
- Use of funds: scaling its drug design engine IsoDDE, building a partner ecosystem, and clinical development infrastructure for its first drug candidates.
- Stage: the company reports positive preclinical results in oncology and immunology, and says it is setting the stage for clinical entry.
In plain English
Isomorphic Labs uses AI models to design new medicine molecules on a computer before anyone tests them in a lab. This new money pays for building better models, for more partnerships with drug makers and for the work needed to move its first candidates into human trials. No Isomorphic drug has entered clinical trials yet.
What happened
The company said the round will accelerate its foundational simulation models, scale its internal and partnered drug candidate pipeline and support “AI-led bioengineering” infrastructure. Hassabis, the founder and CEO, said: “Our drug design engine is generating molecules with unprecedented precision and speed. This round enables us to accelerate our progress: building foundational biology models, deepening our systemic disease understanding, and driving our first therapeutic programs towards clinical trials to deliver tangible impact for patients.”
Max Jaderberg, president of Isomorphic Labs, added: “Every week we are making repeatable scientific advancements enabled by our models.”
Background
Isomorphic Labs was founded in 2021 and spun out of Google DeepMind, building on the protein-structure work behind AlphaFold. It is headquartered in London, with offices in Cambridge, Massachusetts and Lausanne, Switzerland. Its pipeline combines partnered programs and wholly owned internal programs.
How it works
The company’s core system, IsoDDE, is described as a suite of foundational simulation AI models that work across several therapeutic areas and drug modalities. It explores large chemical spaces to propose and refine molecules with drug-like properties. The company also describes proprietary AI agents that reason over complex biological systems. These claims come from the company and have not been independently verified.
Why it matters
For the AI industry, a $5 billion raise is among the largest rounds for an AI company outside the frontier model labs, and it signals that investors see AI-designed medicine as a major commercial category.
For pharma partners and biotech, the fresh capital supports more partnered programs and a faster move toward clinical data, which is the real test of AI drug design.
For Alphabet, its continued backing keeps DeepMind’s science work close to a commercial spin-out.
What’s still open
- The valuation of the company after the round.
- When the first candidate will enter human trials, and how it will perform there.
- Which new pharma partners will join the ecosystem the company describes.
Sources
- Isomorphic Labs, “Isomorphic Labs announces $5 Billion Series C funding,” PR Newswire, 17 November 2026
- Tech.eu, “Sequoia and Greenoaks lead massive $5BN Series C funding round in Isomorphic Labs,” 17 November 2026
i10x Perspective
Drug discovery is one of the few AI fields where success is judged by biology, not benchmarks. A $5 billion round buys time and compute, but trial results will decide whether this is a new industry or an expensive bet. Follow other big rounds in our AI Funding Index and see how other deals compare in Funding & M&A. Alphabet’s wider AI work is on our Google company page.






